One study has demonstrated that MCL-1-binding BH3 mimetics or enhanced PUMA expression can overcome treatment resistance caused by MCL-1 stabilization in CRC cells (Tong et al., 2017). This evidence concerns the gene MCL1 and colorectal carcinoma.